Research Topics
Species | Mitchell S CairoSummaryAffiliation: Columbia University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group reportM S Cairo
Babies and Children s Hospital, Columbia University, New York, New York, USA
J Pediatr Hematol Oncol 23:30-8. 2001..10.0 microg/kg per day) after ifosfamide, carboplatin, and etoposide (ICE) chemotherapy; and 2) to determine the response rate (complete response [CR] + partial response [PR]) of ICE in children with refractory or recurrent solid tumors...- Tumour lysis syndrome: new therapeutic strategies and classificationMitchell S Cairo
Department of Pediatrics, Children s Hospital of New York Presbyterian, Columbia University, New York, NY 10032, USA
Br J Haematol 127:3-11. 2004..We summarise recent advances in the management of TLS and provide a new classification system and recommendations for prophylaxis and/or treatment based on this classification scheme... - Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the futureMitchell S Cairo
Department of Pediatrics, Columbia University, New York, NY 10032, USA
Pediatr Blood Cancer 45:753-69. 2005.... - Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) Study reportMitchell S Cairo
Georgetown University, Washington, DC, USA
Transfusion 45:856-66. 2005..The study goals were to develop standard operating procedures for cord blood (CB) donor recruitment and banking and to build an ethnically diverse unrelated CB bank to support a transplantation protocol... - Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescentsMitchell S Cairo
Morgan Stanley Children s Hospital of New York Presbyterian, Columbia University, New York, NY 10032, USA
Blood 109:2736-43. 2007..001). Standard-intensity FAB/LMB therapy is recommended for children with high-risk B-NHL (B-ALL with or without CNS involvement)... - Alternative allogeneic donor sources for transplantation for childhood diseases: unrelated cord blood and haploidentical family donorsMitchell S Cairo
Morgan Stanley Children s Hospital, New York Presbyterian, Columbia University, New York, New York, USA
Biol Blood Marrow Transplant 14:44-53. 2008..In this article we review the experience of both unrelated cord blood donor and haploidentical family donor transplants in selected pediatric malignant and nonmalignant conditions... - Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological studyMitchell S Cairo
Department of Pediatrics, Columbia University, New York, NY, USA
Br J Haematol 128:49-58. 2005.... - Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experienceMitchell S Cairo
Department of Pediatrics, Children s Hospital New York, Columbia University, New York, NY, USA
Br J Haematol 120:660-70. 2003..001). In summary, the outcome for childhood Burkitt's and Burkitt-like lymphoma has recently improved with the use of short and intensive B-cell non-Hodgkin's lymphoma-directed therapy... - Prevention and treatment of hyperuricemia in hematological malignanciesMitchell S Cairo
Department of Pediatrics, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
Clin Lymphoma 3:S26-31. 2002..In summary, in the prevention and treatment of hyperuricemia, patients with hematological malignancies at risk of tumor lysis syndrome appear to benefit significantly from the use of a recombinant urate oxidase (rasburicase)... - Childhood and adolescent large-cell lymphoma (LCL): a review of the Children's Cancer Group experienceMitchell S Cairo
Department of Pediatrics, Columbia University, New York, New York, USA
Am J Hematol 72:53-63. 2003..Large numbers of patients treated with shorter and intense therapy are required to confirm these preliminary observations... - Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensusMitchell S Cairo
Department of Pediatrics, Columbia University, Morgan Stanley Children s Hospital, NY Presbyterian, New York, NY, USA
Br J Haematol 149:578-86. 2010.... - NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cMitchell S Cairo
Department of Pediatrics, Medicine, and Pathology, Columbia University, Morgan Stanley Children s Hospital, New York Presbyterian Hospital, New York, New York 10032, USA
Biol Blood Marrow Transplant 16:709-28. 2010.... - A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipientsMark B Geyer
Department of Pediatrics, NewYork Presbyterian Morgan Stanley Children s Hospital, Columbia University, New York, NY, USA
Br J Haematol 155:218-34. 2011..The use of adoptive cellular immunotherapy to accelerate immune reconstitution and prevent and treat opportunistic infections and malignant relapse following UCBT warrants further investigation... - A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimPrakash Satwani
Department of Pediatric, New York Presbyterian Morgan Stanley Children s Hospital, Columbia University, New York, NY, USA
Biol Blood Marrow Transplant 18:324-9. 2012..8-73.6). GO combined with Bu/Cy regimen followed by alloSCT is well tolerated in children with poor-risk AML. GO at 7.5 mg/m(2) in combination with Bu/Cy is currently being tested in a phase II study... - Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemiaElizabeth Roman
Department of Pediatrics, Columbia University, New York, New York 10032, USA
Clin Cancer Res 11:7164s-7170s. 2005..Additional studies in a larger group of patients will be required to adequately assess the safety of this approach... - Differential gene expression signatures of adult peripheral blood vs cord blood monocyte-derived immature and mature dendritic cellsHong Jiang
Department of Pediatrics, Morgan Stanley Children s Hospital New York Presbyterian, Columbia University, New York, NY 10032, USA
Exp Hematol 37:1201-15. 2009..Our previous studies have demonstrated differentially expressed genetic signature patterns in adult peripheral blood (APB) monocytes (Mos) vs cord blood (CB) Mos... - A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology GroAnne L Angiolillo
Children s National Medical Center, George Washington University, Washington, DC, USA
Clin Cancer Res 11:2644-50. 2005..2, 2.4, or 3.6 microg/kg per dose... - An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipientsMonica Bhatia
Department of Pediatrics, Columbia University, New York, NY 10032, USA
Biol Blood Marrow Transplant 16:333-43. 2010..Children <12 years of age appear to have a significantly different MPA PK profile compared to older children and adolescents and may require more frequent dosing... - Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapyJanet Ayello
Department of Pediatrics, Morgan Stanley Children s Hospital of New York Presbyterian Hospital and Columbia University, New York, NY 10032, USA
Exp Hematol 37:1216-29. 2009.... - Risk factors associated with kidney injury and the impact of kidney injury on overall survival in pediatric recipients following allogeneic stem cell transplantPrakash Satwani
Department of Pediatrics, New York Presbyterian Morgan Stanley Children s Hospital, Columbia University, New York, NY, USA
Biol Blood Marrow Transplant 17:1472-80. 2011..31, P = .013), no KI versus KI (HR 2.00, P = .005). In children, MAC is associated with significant risk of KI in the first month after transplant, and KI in the first month post-AlloSCT is associated with a significantly decreased OS... - Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipientsPrakash Satwani
Department of Pediatrics, Morgan Stanley Children s Hospital of New York Presbyterian, Columbia University, New York, New York 10032, USA
Biol Blood Marrow Transplant 15:1587-95. 2009..4-210.8; P=< .01). Overall infection-related mortality was only 1.1% (1/86) for SVIs and 2.3% (2/86) for IFIs. Our data indicate that RIC allo-SCT does not carry a lower risk of SVIs and IFIs than MAC allo-SCT in pediatric recipients... - A low incidence of nontuberculous mycobacterial infections in pediatric hematopoietic stem cell transplantation recipientsElif Unal
Department of Pediatrics, Columbia University, New York, New York 10032, USA
Biol Blood Marrow Transplant 12:1188-97. 2006..Multicenter studies are needed to identify the risk factors, early diagnostic criteria, and optimal therapy... - Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseasesPrakash Satwani
Department of Pediatrics, Columbia University, New York, New York, USA
Pediatr Blood Cancer 50:1-8. 2008.... - Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineeringJanet Ayello
Department of Pediatrics, Columbia University, New York, New York 10032, USA
Biol Blood Marrow Transplant 12:608-22. 2006..005, respectively). These data suggest that cryopreserved CB cells could be ex vivo engineered for potential use as adoptive cancer cellular immunotherapy for donor lymphocyte infusion after CBT... - Adenovirus infection in paediatric allogeneic stem cell transplantation recipients is a major independent factor for significantly increasing the risk of treatment related mortalityDiane George
Department of Pediatrics, NewYork Presbyterian Morgan Stanley Children s Hospital, Columbia University, New York, NY 10032, USA
Br J Haematol 156:99-108. 2012.... - Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challengesPrakash Satwani
Department of Pediatrics, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York 10032, USA
Biol Blood Marrow Transplant 11:403-22. 2005..We review the recent experience of RI AlloSCT in adults and children with both malignant and nonmalignant diseases and discuss the challenges for the future... - Unrelated umbilical cord blood transplantation and immune reconstitutionPaul Szabolcs
Department of Pediatrics, Division of Pediatric Bone Marrow Transplantation, Duke University Medical Center, Durham, NC, USA
Semin Hematol 47:22-36. 2010..Novel cellular therapies that are about to enter the clinical setting in the form of natural killer (NK) cell and T-cell therapies in the form of donor lymphocyte infusion (DLI) are also discussed... - Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantationElizabeth Roman
Department of Pediatrics, Columbia University, New York, New York, USA
Pediatr Blood Cancer 50:325-30. 2008..We initiated a pilot study to determine the safety and activity of prophylactic liposomal amphotericin B (AMB) in preventing IMI in pediatric and adolescent AlloSCT recipients during the first 100 days... - Dysregulation of expression of immunoregulatory and cytokine genes and its association with the immaturity in neonatal phagocytic and cellular immunityPrakash Satwani
Department of Pediatrics, Columbia University, New York, NY 10032, USA
Biol Neonate 88:214-27. 2005.... - Prophylactic use of myelopoietic growth factors in children after myelosuppressive and myeloablative therapyPrakash Satwani
Department of Pediatrics, Children's Hospital New York-Presbyterian, Columbia University, 161 Fort Washington, Irving 7, New York, NY 10032, USA
Curr Hematol Rep 2:480-90. 2003..Additional pediatric studies comparing the safety, efficacy, and cost effectiveness of granulocyte colony-stimulating factor versus granulocyte macrophage colony-stimulating factor are needed... - Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioningIan M Waxman
Department of Pediatrics, Columbia University, New York, NY 10032, USA
Pediatr Transplant 13:464-74. 2009..In summary, it was demonstrated that sequential administration of GM-CSF/G-CSF post-MA-alloSCT was safe, cost-effective and resulted in prompt myeloid engraftment... - Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescentsThomas G Gross
Department of Pediatrics, Nationwide Children s Hospital, Ohio State University, Columbus, Ohio 43205, USA
Biol Blood Marrow Transplant 16:223-30. 2010..These data were unable to demonstrate a difference in outcome by donor type for the other histological subtypes... - Interleukin (IL)-15 in combination with IL-2, fms-like tyrosine kinase-3 ligand and anti-CD3 significantly enhances umbilical cord blood natural killer (NK) cell and NK-cell subset expansion and NK functionPrakash Satwani
Department of Pediatrics, Columbia University, New York, New York 10032, USA
Cytotherapy 13:730-8. 2011..Previously, we have demonstrated significant ex vivo expansion and activation of unrelated cord blood (UCB) NK cells with an antibody/cytokine cocktail consisting of anti-CD3 + IL-2 + IL-12 + IL-7 and anti-CD3 + IL-2 + IL-12 + IL-18... - A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipientsEvan B Shereck
Department of Pediatrics, Columbia University, and Division of Pediatric Hematology and Blood and Marrow Transplantation, Morgan Stanley Children s Hospital of New York Presbyterian, Herbert Irving Comprehensive Cancer Center, New York, NY 10032, USA
Pediatr Blood Cancer 49:306-12. 2007..We hypothesized that alternate day ganciclovir and foscarnet for the prevention of CMV during the first 100 days after AlloSCT would be safe and effective... - Immaturity of IL-18 gene expression and protein production in cord blood (CB) versus peripheral blood (PB) mononuclear cells and differential effects in natural killer (NK) cell development and functionPrakash Satwani
Department of Pediatrics, Columbia University, New York, NY, USA
Br J Haematol 130:284-92. 2005..These results may have implications for the mechanism(s) in part responsible for the immaturity of CB T-cell immunity... - Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study reportPrakash Satwani
Morgan Stanley Children s Hospital of NewYork Presbyterian, Columbia University, New York, New York 10032, USA
Biol Blood Marrow Transplant 13:218-27. 2007..Randomized prospective cooperative group studies are required to establish the role of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in children with UHRF ALL in CR1... - Myeloid hematopoietic growth factors and their role in prevention and/or treatment of neonatal sepsisElvira Parravicini
Divisions of Pediatric Oncology and Neonatology, Department of Pediatrics, Columbia University, New York, NY, USA
Transfus Med Rev 16:11-24. 2002.... - CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantationManuela A Orjuela
Departments of Pediatrics, Columbia University, New York Presbyterian Morgan Stanley Children s Hospital New York, NY, USA
Br J Haematol 152:733-42. 2011..56·3%, P = 0·01). EBV expression was unrelated to PTLD-related EFS or OS. CD20 expression is associated with timing of development of PTLD and predicts survival in PTLD diagnosed following paediatric SOT... - Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cellsMunenari Itoh
Departments of Dermatology, Columbia University, New York, NY 10032, USA
Proc Natl Acad Sci U S A 108:8797-802. 2011..Our studies indicate that autologous iPSCs have the potential to provide a source of cells for regenerative therapies for specific skin diseases... - Immunotherapy in the prophylaxis and treatment of neonatal sepsisMandhir Suri
Children's Hospital of New York Presbyterian, Divisions of Pediatric Oncology and Neonatology, and Department of Pediatrics, Columbia University, New York, New York, USA
Curr Opin Pediatr 15:155-60. 2003.... - A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipientsIfeyinwa Osunkwo
Department of Pediatrics, Children's Hospital of New York-Presbyterian, Columbia University, New York, New York, USA
Biol Blood Marrow Transplant 10:246-58. 2004..Further pharmacokinetic and pharmacodynamic studies are ongoing in pediatric and adolescent AlloSCT recipients to define optimal MMF dosing... - Cord blood immunology and stem cell transplantationM Brigid Bradley
Department of Pediatrics, Columbia University, New York, NY 10032, USA
Hum Immunol 66:431-46. 2005.... - Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot StudyElizabeth A Raetz
Department of Pediatrics, New York University, School of Medicine, Hassenfeld Children s Center for Cancer and Blood Disorders, New York, NY 10016, USA
J Clin Oncol 26:3756-62. 2008.... - The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromesMonica Bhatia
Departments of Pediatrics, Morgan Stanley Children s Hospital of New York Presbyterian, Columbia University, New York, NY 10032, USA
Leuk Lymphoma 48:9-15. 2007.... - A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group studyErin Cooney Qualter
Division of Pediatric Heamtology and Blood and Marrow Transplantation, Medicine and Pathology, Columbia University, New York, New York 10032, and Children s Hospital of Philadelphia, PA, USA
Clin Cancer Res 13:5652s-5660s. 2007..There is no data on the safety and feasibility of 90Y-IT in refractory childhood CD20+ lymphoma... - B large-cell lymphoma in children and adolescentsElizabeth Raetz
Mount Sinai School of Medicine, 1 Gustave Levy Place, 1208, New York, NY 10029, USA
Cancer Treat Rev 29:91-8. 2003.... - Cord blood transplantation and stem cell regenerative potentialYanling Liao
Department of Pediatrics, New York Presbyterian Morgan Stanley Children s Hospital, Columbia University, New York, NY 10032, USA
Exp Hematol 39:393-412. 2011..In this review, we will summarize the most recent updates on clinical applications of cord blood transplantation and the promises and limitations of cell-based therapies for tissue repair and regeneration... - Treatment of severe thrombocytopenia with IL-11 in children with Wiskott-Aldrich syndromeKiery Braithwaite
Department of Pediatrics and the Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
J Pediatr Hematol Oncol 24:323-6. 2002..Larger studies are required to confirm this observation of the safety and efficacy of IL-11 in this setting... - Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approachesGustavo del Toro
Division of Pediatric Hematology, Columbia University, 180 Fort Washington Avenue, New York, NY 10032, USA
Clin Adv Hematol Oncol 3:54-61. 2005..Special emphasis is placed on the use of a relatively new agent, rasburicase, as an alternative to allopurinol in the management of TLS-associated hyperuricemia... - A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantationManuela Orjuela
Departments of Pediatrics, Columbia University, New York, New York 10032, USA
Clin Cancer Res 9:3945S-52S. 2003..Future prospective larger trials with longer follow-up investigating this combination will be required to confirm these preliminary results... - Increased induction of allogeneic-specific cord blood CD4+CD25+ regulatory T (Treg) cells: a comparative study of naïve and antigenic-specific cord blood Treg cellsChih-Chao Chang
Department of Pediatrics, Columbia University, New York, NY 10032, USA
Exp Hematol 33:1508-20. 2005.... - Prophylactic use of myelopoietic growth factors in children after myelosuppressive chemotherapy: does it pay?Olga Bessmertny
Department of Pharmacy, Children's Hospital of New York Presbyterian, Columbia University, New York 10032, USA
J Pediatr Hematol Oncol 25:435-40. 2003 - Periostitis secondary to interleukin-11 (Oprelvekin, Neumega). Treatment for thrombocytopenia in pediatric patientsEdward Milman
Department of Radiology, Division of Pediatric Radiology, Children's Hospital of New York-Presbyterian, 3959 Broadway, CHN 3-325, New York, NY 10032, USA
Pediatr Radiol 33:450-2. 2003..The pediatric doses (75 g/kg/d) are above those recommended for adult patients (50 g/kg/d) and this may account for the pediatric bone changes of periostitis... - Human natural killer cells in health and diseaseEvan Shereck
Department of Pediatrics, Columbia University, New York, New York, USA
Pediatr Blood Cancer 49:615-23. 2007..Further studies are required to determine optimal selection of donors and recipients, both on NKR matching/mismatching, undergoing haploidentical and unrelated hematopoetic stem cell transplantation... - Rasburicase: a new approach for preventing and/or treating tumor lysis syndromeOlga Bessmertny
Department of Pharmacy, Children's Hospital of New York Presbyterian, Columbia University, NY 10032, USA
Curr Pharm Des 11:4177-85. 2005.... - Central neurocytoma responsive to topotecan, ifosfamide, carboplatinElham Amini
Department of Pediatrics, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
Pediatr Blood Cancer 51:137-40. 2008..The complete response of central neurocytoma to chemotherapy only reported here should be helpful to those caring for patients with this rare tumor... - Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7. Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantationKathleen L Robinson
Department of Pediatrics, Georgetown University, Washington, DC, USA
Exp Hematol 30:245-51. 2002..Further studies, however, are required to determine whether these ex vivo--expanded MNC could also potentially exacerbate acute or chronic graft-vs-host disease and/or other toxicities if utilized post-UCBT... - The potential of umbilical cord blood multipotent stem cells for nonhematopoietic tissue and cell regenerationCarmella van de Ven
Department of Pediatrics, Columbia University and Morgan Stanley Children s Hospital New York Presbyterian, New York, NY 10032, USA
Exp Hematol 35:1753-65. 2007..This review will summarize the in vitro and in vivo studies examining UCB stem cells and their potential use for therapeutic application for nonhematopoietic tissue and cell regeneration... - Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the scienceJessica Hochberg
Department of Pediatrics, Columbia University, New York, NY 10032, USA
Br J Haematol 144:24-40. 2009.... - Differential gene expression patterns by oligonucleotide microarray of basal versus lipopolysaccharide-activated monocytes from cord blood versus adult peripheral bloodHong Jiang
Department of Pediatrics, Children's Hospital of New York-Presbyterian, Columbia University, New York, NY 10032, USA
J Immunol 172:5870-9. 2004..These results provide insight into the molecular basis for normal genetic regulation of Mo development and cellular function and differential inflammatory and innate and adaptive immune responses between activated CB and APB Mo... - Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patientsKenneth R Meehan
Division of Hematology and Oncology, Bone Marrow Transplant Program, Georgetown University Medical Center and the Vincent T Lombardi Cancer Center, Washington, DC 20007, USA
J Hematother Stem Cell Res 11:415-21. 2002..These results demonstrate that paclitaxel with rhG-CSF is an efficient mobilizing agent in high-risk breast cancer patients... - Rasburicase: future directions in tumor lysis managementJessica Hochberg
Columbia University, Morgan Stanley Children s Hospital of NewYork Presbyterian, Division of Pediatric Hematology Oncology Blood and Marrow Transplantation, Department of Pediatrics, 3959 Broadway, CHN 10 03, New York, NY 10032, USA
Expert Opin Biol Ther 8:1595-604. 2008..Rasburicase is a safe and effective hypouricemic agent for both adults and children at high risk for TLS and for this reason should be considered the uricolytic agent of choice in these patients... - Recombinant urate oxidase (rasburicase): a new targeted therapy for prophylaxis and treatment of patients with hematologic malignancies at risk of tumor lysis syndromeMitchell S Cairo
Department of Pediatrics, Columbia University, New York, NY, USA
Clin Lymphoma 3:233-4. 2003
Research Grants
- Nonablative AlloSCT in Refractory Autoimmune DiseaseMitchell Cairo; Fiscal Year: 2003....
- First Int'l Symposium on Childhood and Adolescent NHLMitchell Cairo; Fiscal Year: 2003..abstract_text> ..